- Home
- CVKD vs BCDA Comparison
CVKD vs BCDA Comparison
Compare CVKD & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CVKD | BCDA |
|---|---|---|
| Founded | 2022 | N/A |
| Country | United States | United States |
| Employees | N/A | 17 |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.3M | 12.4M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | CVKD | BCDA |
|---|---|---|
| Price | $8.30 | $1.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $32.00 | $25.00 |
| AVG Volume (30 Days) | 48.5K | ★ 56.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.91 | $1.00 |
| 52 Week High | $20.39 | $3.20 |
Technical Indicators
Market Signals| Indicator | CVKD | BCDA |
|---|---|---|
| Relative Strength Index (RSI) | 62.07 | 57.42 |
| Support Level | $6.64 | $1.24 |
| Resistance Level | $8.79 | $1.33 |
| Average True Range (ATR) | 0.64 | 0.08 |
| MACD | 0.40 | 0.02 |
| Stochastic Oscillator | 87.03 | 80.43 |
Price Performance
Historical ComparisonAbout CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).